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Henk Timmerman – Vrije Universiteit, The NetherlandsAntibodies and their derivatives radiolabelled with
positron- and gamma-emitting radiometals enable sen-
sitive and quantitative molecular Positron Emission
Tomography (PET) and Single Photon Emission Com-
puted Tomography (SPECT) imaging of antibody dis-
tribution in vivo. Chelators that are covalently attached
to antibodies allow radiolabelling with metallic PET
and SPECT radioisotopes. Conventional strategies
for chelator-protein conjugation generate heteroge-
neous mixtures of bioconjugates that can exhibit re-
duced afﬁnity for their receptor targets, and
undesirable biodistribution and pharmacokinetics. Re-
cent advances in bioconjugation technology enable site-
speciﬁc modiﬁcation to generate well-deﬁned con-
structs with superior properties. Herein we survey
existing site-speciﬁc chelator-protein conjugation
methods. These include chelator attachment to
cysteines/disulﬁde bonds or the glycan region of the
antibody, enzyme-mediated chelator conjugation, and
incorporation of sequences of amino acids that chelate
the radiometal. Such technology will allow better use of
PET and SPECT imaging in the development of anti-
body-based therapies.Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
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Introduction
Monoclonal antibodies (mAbs) have demonstrated exquisite
sensitivity and selectivity for their target cell surface receptors
in vivo [1]. As well as being important in clinical therapies
[2,3], mAbs can be used as in vivo vectors, to deliver an
additional therapeutic payload (e.g. small-molecule cytotox-
ic compounds [4–6] or radiotherapeutic isotopes [7,8]) or, in
combination with an imaging probe (e.g. a gamma or posi-
tron-emitting radionuclide, or an optically active molecule),
to visualize the in vivo distribution of target cell surface
receptors.
Antibodies labelled with a gamma- or positron-emitting
radionuclide can be used to quantitatively image the biodis-
tribution of the radiolabelled-antibody using whole body
Single Photon Emission Computed Tomography (SPECT)
or Positron Emission Tomography (PET) respectively. Such
radiolabelled mAbs are extremely useful for both preclinical
and clinical development of antibody-based therapies, en-
abling (i) non-invasive detection of the target receptors’
expression, including any potential heterogeneity in expres-
sion, (ii) estimation of an antibody’s biodistribution, thera-
peutic index and pharmacokinetics by quantification of
antibody distribution in target and normal tissues, and (iii)
prediction and assessment of a patient’s response to a specific
mAb therapy by imaging with the radiolabelled antibody [9].ion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
under the CC BY license (http://creativecommons.org/licenses/by/4.0/). https://doi.org/
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DDTEC-566; No of Pages 14Radioactive metal ions are well-suited to radiolabelling
antibodies for PET and SPECT imaging. Compared to non-
metallic radionuclides, radiometals allow for simple radiola-
belling procedures: typically, a chelator is firstly covalently
attached to the antibody, and once conjugated, the chelator
binds the radiometal. The half-lives of many of the metallic
radionuclides, including zirconium-89 [9] (78 h half-life) for
PET, and indium-111 [10] (67 h half-life) for SPECT, more
closely match the time required for antibodies to clear circu-
lation and accumulate in target tissue (1 day–1 week) than
non-metallic radionuclides such as fluorine-18 (119 min half-
life). Antibodies labelled with PET, SPECT and radiotherapeu-Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002
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Fig. 1. Structure of IgG1 antibodies and smaller, engineered fragment antibod
2 www.drugdiscoverytoday.comtic radioisotopes of iodine have been extensively studied both
preclinically and clinically [11], however, many of these are
subject to deiodination in vivo. Advances in radiochemical
methodology have increased stability of radioiodine-anti-
body constructs [12,13], however, this is beyond the scope
of this review.
Antibody structure
Immunoglobulin type 1 antibodies (Fig. 1) (IgGs) are the
most commonly used type of mAb for pharmaceutical appli-
cations. They are approximately 150 kDa, and are composed
of two identical polypeptide ‘‘heavy chains’’ paired with twoion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
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(Fab) region, a fragment crystallisable (Fc) region, two disul-
fide bonds in the hinge region and a conserved glycosylated
position at N297 of each heavy chain [1,5]. Smaller deriva-
tives of IgGs that include the targeting variable region of the
Fab region have also been engineered. Although they gener-
ally exhibit lower accumulation at disease sites, they clear
circulation faster than full-length IgGs [14]. Recently de-
scribed radiolabelled-immunoconjugates include both full-
length IgG mAbs, and smaller fragment derivatives [14,15].
Radionuclide imaging with these smaller derivatives has
shown that high ‘‘target to non-target’’ contrast can be
achieved at early time points (1–12 h) following radiotracer
administration. In contrast, full-length IgG antibodies re-
quire significantly greater time periods (1 day–1 week) to
enable the antibody to accumulate at target tissue and clear
circulation.
Chelators for radiometal-antibody imaging
Metallic radioisotopes are incorporated into an antibody via a
chelator. Many factors influence the choice of a metallic
radioisotope, including the imaging modality (PET or
SPECT/g-scintigraphy imaging), matching of the half-life of
the radioisotope to the pharmacokinetics of the vector, and
the availability of the radioisotope itself. The chelator binds
the radiometal, and the resulting radiometal–chelator com-
plex will ideally possess both high thermodynamic and ki-
netic stability. This high stability is essential to ensure that
the radiometal remains bound to the antibody in vivo. We
[16–18] and others [19–21] have reviewed existing and new
chelator technology for radiometal-based PET and SPECT
imaging. Here, we simply include a list of commonly used
imaging radiometals (Table 1) for ease of reference.
Attaching chelators to antibodies
In chelator-antibody conjugation reactions, the antibody and
chelator contain complementary reactive functional groups
for attachment to each other. There are several requirements
for this covalent attachment:Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002
Table 1. Decay properties and production methods for selected
Radiometal Half-life Mode of decay (%)
99mTc 6.0 h ITa (100)
111In 2.83 d ECb (100)
67Ga 3.27 d EC (100)
68Ga 68 min b+c (90)
89Zr 78.4 h EC (77) b+ (23)
64Cu 12.7 h b+ (18) EC (43)
bd (39)
a IT = isomeric transition.
b EC = electron capture.
cb+ = positron emission.
d b = beta emission.(i) mild conjugation (and subsequent radiolabelling) reac-
tion conditions are essential to preserve the tertiary and
quaternary structure of the antibody;
(ii) the new covalent link between the chelator and protein
must be stable under physiological conditions; and
(iii) the covalent modification must not compromise the
binding affinity and specificity of the protein.
Most of the conventional functionalities used to attach
chelators to proteins consist of reactive electrophilic groups
such as isothiocyanates, N-hydroxysuccinimide esters (Fig. 2)
and anhydrides that react with solvent accessible primary
amines of lysine side chains, and maleimides that attach via
Michael addition to the thiols of reduced cysteine side chains
(Fig. 3a) [18,22–26].
In these conventional conjugation reactions, the presence of
multiple solvent-accessible amino acids in proteins leads to a
lack of both stoichiometric control and site-specificity. The
resulting heterogeneous mixtures of chelator-protein conju-
gates can exhibit suboptimal pharmacokinetics and decreased
affinity for target receptors [27–29]. Additionally, the heteroge-
neous nature of the conjugates is potentially a barrier to regula-
tory approval of their clinical application and development.
Significant efforts over the last decade have resulted in new
site-selective conjugation methods for attaching chelators
and other cargoes (fluorescent molecules, small molecular
weight drugs) to antibodies [30–39]. Such an approach (often
described as orthogonal) uses complementary pairs of func-
tional groups that react chemoselectively with each other. It
involves appending one functional group to the chelator, and
the other to the protein, followed by reaction between the
two motifs. Ideally, this reaction will proceed in water at near-
neutral pH and ambient temperature (25–37 C) to avoid
protein denaturation or degradation.
‘‘Click chemistry’’ is one such approach [40,41]: for exam-
ple, engineering cyclooctyne and azide groups into a chelator
and antibody to give a triazole-containing bioconjugate, can
provide this desired chemoselectively. However, this ap-
proach requires modification of the antibody prior to the
conjugation reaction itself, and if the azide/octyne is incor-ion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
 radiometals used in PET and SPECT imaging.
 Production mode Application
99Mo/99mTc generator SPECT
111Cd(p,n)111In SPECT
68Zn(p,2n)67Ga SPECT
68Ge/68Ga generator PET
89Y(p,n)89Zr PET
64Ni(p,n)64Cu PET
www.drugdiscoverytoday.com 3
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Fig. 2. Conventional bioconjugation methods used for lysine modiﬁcation in nuclear imaging: (a) N-hydroxysuccinimide ester and (b) isothiocyanate
derivatives are commonly used. We illustrate attachment of a NOTA (1,4,7-triazacyclononane-N,N0 ,N00-triacetetate) chelator and a THP (tris
(hydroxypyridinone)) chelator. Metal complex charges are excluded.porated via a non-specific lysine modification, as is often the
case, site-selectivity is not actually achieved [42–45]. There
are elegant examples in which reactive ‘‘click’’ groups have
been site-selectively introduced into antibodies [30,46], and
examples are included in relevant sections below.
Here, we capture an overview of site-selective conjugation
methods used to prepare radiometal-labelled antibodies and
antibody derivatives for PET and SPECT imaging. This includes
site-directed modification of cysteines/disulfide bonds and the
glycan region of the antibody, enzyme-mediated conjugation,Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002
4 www.drugdiscoverytoday.comand incorporation of sequences of amino acids that coordinate
the radiometal. Others have also recently reviewed this area,
including an elegant and detailed survey of site-selective anti-
body conjugation methods used for molecular imaging with
both optical and radionuclide imaging labels, and site-selective
methods to incorporate radiotherapeutic isotopes [47,48].
Cysteine modiﬁcation
Cysteines are useful for selective protein modification for
several reasons:ion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
Vol. xxx, No. xx 2018 Drug Discovery Today: Technologies |
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MeO2S
Fig. 3. Thiol-reactive compounds including (a) maleimide, (b) pyridyldithiopropionate, (c) methylsulfonyl phenyloxadiazole, (d) monobromo malelimide
and (e) carbonylacrylic derivatives of chelators and ﬂuorophores can be used to incorporate chelators into antibodies and their derivatives. Here we also
illustrate incorporation of a 89Zr-DFO (desferrioxamine) chelator and an 111In-DTPA (diethylenetriamine pentaacetate) chelator. Metal complex charges
are excluded.(i) cysteine has a low abundance (1–2%) in living organisms
[49,50], and so the probability of adversely affecting the
pharmacokinetics of proteins by attachment of too
many chelators is relatively low;
(ii) the nucleophilicity of the cysteine deprotonated thiol
group (pKa of  8.3) exceeds the reactivity of other
nucleophilic groups of amino acids in proteins [51,52];
(iii) single, solvent-exposed cysteine residues can be engi-
neered into antibodies and their derivatives [53,54],
enabling site-selective attachment of cargo, including
radiolabelled chelators. In many cases, such cysteines are
introduced at the carboxyl terminus of the protein, to
minimise the likelihood that the modification will im-Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002pair protein structure and activity. These new cysteine
residues are often ‘‘capped’’ by a single cysteine amino
acid or thiol-containing small molecule [55], or form
protein homodimers via intermolecular disulfide bonds
[56]. Thus, a reduction step is required to generate a
reduced thiol for subsequent conjugation. Full-length
antibodies [57] and other small proteins [58,59] have
been modified using this approach.
Conjugation via C–S bonds
The most widely employed method of conjugating antibodies
via cysteines involves a Michael addition reaction of a thiolion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
www.drugdiscoverytoday.com 5
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(Fig. 3a).
Radionuclide imaging studies have demonstrated that suc-
cinimidyl thioether linkages have superior stability compared
to disulfide linkages. For example, maleimide and pyridyl-
dithiopropionate (Fig. 3a/b) groups appended to DTPA che-
lators have been reacted with terminal cysteine residues of an
anti-carcinoembryonic Fab’ [60]. The new DTPA-Fab’ conju-
gates were radiolabelled with 111In, and their biodistribution
assessed in mice bearing colorectal carcinoma tumours. The
(maleimide-derived) thioether-linked radiotracer enabled ef-
ficient tumour targeting, whereas the (pyridyldithiopropio-
nate-derived) disulfide-bridged analogue showed poor
biodistribution with high kidney uptake and poor tumour
targeting, due to in vivo cleavage of the S–S linkage.
Maleimide derivatives have been widely used to incorpo-
rate chelators, via cysteine thiols, into antibody derivatives
and proteins [26,55–59], and many chelator-maleimide
reagents are commercially available. However, maleimide
conjugates suffer from instability: the thioether can undergo
a retro-Michael reaction, converting back to the starting thiol
and maleimide. The maleimide motif, still attached to its
payload, reacts with endogenous molecules containing bio-
available thiols, such as glutathione and albumin [61–64]. In
radionuclide imaging, this can potentially result in accumu-
lation of radioactivity at off-target sites, decreasing image
contrast, sensitivity and the ability to quantify protein bio-
distribution.
Several new cysteine-reactive reagents that provide en-
hanced conjugate stability have been developed [64–67].
Following reduction of antibody disulfide bonds (typically
with tris(2-carboxyethyl)phosphine hydrochloride), methyl-
sulfonyl phenyloxadiazole (Fig. 3c) derivatives bearing DFO
and DTPA chelators have been selectively attached to
cysteines of trastuzumab, cetuximab and huA33 antibodies
[68,69]. These chelator-antibody conjugates contained an
average of 1.4–2.2 chelators per antibody and gave 89Zr-
DFO-mAbs and radiotherapeutic 177Lu-DTPA-mAbs that
demonstrated higher C–S bond stability in serum than mal-
eimide derivatives. Furthermore, methylsulfonyl phenylox-
adiazole-derived 89Zr-DFO-huA33 antibody demonstrated
superior in vivo targeting behaviour compared to its malei-
mide-derived analogue: the former resulted in higher tu-
mour-to-background activity ratios in a murine model
bearing huA33 antigen-expressing colorectal cancer xeno-
grafts.
Monobromo maleimide (Fig. 3d) [67,70] and carbony-
lacrylic (Fig. 3e) [71] reagents have been used to generate
stable protein conjugates via native, single accessible
cysteines, although to date, they have not been used in
radionuclide imaging. Monobromo maleimides enable sub-
stitution of the bromo group by a reactive thiol, generating a
thiol-maleimide that can be hydrolysed (ring-opened) to givePlease cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002
6 www.drugdiscoverytoday.coma C–S bond that is stable to undesirable retro-Michael decon-
jugation [67,70].
Modifying antibody disulﬁde bridges
Single cysteine-targeted conjugation strategies are well-suited
for site-specific modification of Fab or scFv fragments that
contain single, exposed cysteine residues, however, they are
not ideal for generating well-defined conjugates of IgG anti-
bodies. IgG proteins contain four solvent-accessible inter-
chain disulfide bridges in the protein hinge region, and
their reduction creates eight reactive thiols. Conjugation to
these reduced species results in heterogeneous mixtures of
conjugates, and the cleavage and modification of these disul-
fide bridges (with up to eight copies of cargo) can lead to
adverse pharmacokinetics, and reduce the metabolic stability
of IgG antibodies in plasma [72,73]. Additionally, reduced
thiol groups that do not participate in bioconjugate reactions
can undergo oxidative intramolecular reactions with other
thiols, often resulting in disulfide scrambling that disrupts
the structure and function of the protein.
Recent research has produced functional species that
react with two reduced thiol groups of antibodies, thus
enabling concomitant attachment of functional groups
(for example, fluorophores) and re-bridging of two
cysteines. It is important that the re-bridging motif reacts
rapidly with both disulfide-derived reduced thiols, to avoid
incorrect re-bridging, and thus preserve structure and func-
tion of the protein [74–76], and that the resulting re-
bridged covalent bonds are unreactive towards serum
thiols. Novel thiol-stable chemical technologies have been
successfully applied to modification of disulfide bonds in
mAbs and their derivatives. These include bissulfone deri-
vatives (Fig. 4a) [77–80], dibromoalkyl oxetane derivatives
[81] (Fig. 4b), trivalent arsenous acid [82], dibromopyrida-
zinediones (Fig. 4c) [73,83], and disubstituted maleimides
(Fig. 4d) [84–88]. Bridged bisthiomaleimide (derived from
disubstituted maleimides) can be hydrolysed to dithioma-
leamic acid under mildly basic conditions, generating ho-
mogenous antibody conjugates that are unreactive towards
serum thiols and do not undergo retro-Michael reactions in
biological media, unlike conventional maleimide deriva-
tives [85,89,90]. These technologies have not been applied
to radionuclide imaging, but could be advantageous for
future antibody-based radionuclide imaging.
Glycan modiﬁcation
IgG proteins contain two conserved post-translational modi-
fication glycosylation sites (Fig. 1) that can be chemically
modified to enable site-selective attachment of chelators.
This conjugation strategy is appealing because:
(i) modification at these sites will not compromise antigen
binding properties as they are distal to the Fab region;ion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
Vol. xxx, No. xx 2018 Drug Discovery Today: Technologies |
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Fig. 4. New conjugation technology that enables disulﬁde rebridging includes derivatives based on (a) bissulfone, (b) dibromoalkyl oxetane, (c)
dibromopyridazinediones and (d) dibromo/dithiophenyl maleimides. This technology has not been applied to radionuclide-labelling of antibodies, but is a
promising future avenue.(ii) there are two attachment sites available per antibody;
and
(iii) there are several chemoselective/orthogonal reactions
enabling modification of glycans and hexose groups.
This method is not suitable for smaller antibody fragments
that lack glycans, or for IgG1 antibodies whose function
requires the presence of the native (unmodified) Fc regions
for binding to Fc-receptors (such as those involved in im-
mune responses).
Importance of glycan modiﬁcation chemistry to clinical antibody
imaging
Glycan-based modification chemistry has been critically im-
portant in the clinical development of molecular imaging with
antibodies in nuclear medicine [91]. The first FDA-approved
imaging radioimmunoconjugate specifically incorporated 111
In into the satumomab antibody via a DTPA chelator at the
glycan region (see below). 111In-DTPA-satumomab targets a
tumour-associated glycoprotein, TAG-72, expressed in several
cancers, including colorectal and ovarian cancers [92]. Clinical
g-scintigraphy and SPECT imaging trials in over 1000 patients
have demonstrated 111In-DTPA-satumomab’s utility in detect-Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002ing colorectal and ovarian cancer lesions, and in combination
with other diagnostic tests, informing clinical decision-mak-
ing, including treatment and surgery.
Another FDA-approved antibody imaging agent, 111In-capro-
mab pendetide (also known as Prostascint), similarly incorpo-
rates a DTPA chelator using this glycan technology [91]. 111In-
capromab pendetide targets the prostate specific membrane
antigen (PSMA) expressed in prostate cancer, and has demon-
strated potential in assisting in (i) the staging of prostate cancer,
particularly in identifying soft tissue metastases, and (ii) locating
prostate cancer tumours when diagnostic blood tests indicate
disease recurrence [93]. Although111In-capromab pendetide has
not demonstrated high positive predictive value and specificity
for clinical management of prostate cancer, it has been funda-
mentally important in the development of radionuclide molec-
ular PET and SPECT imaging of its target, PSMA. Several PSMA-
targeted PET and SPECT imaging agents are currently being
clinically developed [94–97], after showing high diagnostic
utility in prostate cancer management.
Reaction with oxidised hexose groups
One of the most widely used methods for site-specific modi-
fication of glycan sites relies on the generation of an aldehydeion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
www.drugdiscoverytoday.com 7
Drug Discovery Today: Technologies | Vol. xxx, No. xx 2018
DDTEC-566; No of Pages 14group by oxidising the cis-glycol groups of terminal hexoses
(Fig. 5a–c), commonly with sodium periodate [33,98–100].
The generated aldehydes can be reacted with chelator
derivatives containing pendant primary amines, generating
an imine conjugate. The resulting imine conjugate can be
further modified by reduction with cyanoborohydride to
form an amine, preventing in vivo hydrolysis of the newly
generated linker (Fig. 5a) [101]. 111In-DTPA-satumomab and
111In-capromab pendetide both incorporate DTPA chelators
via this strategy [91]. Compared to antibodies in which the
radiolabel is incorporated via solvent-accessible lysines, radi-
olabelling via site-specific glycan modification leads to in-
creased radioactivity accumulation in tumours and decreased
off-target tissue radioactivity concentration [91,102].
Aldehydes of modified glycans can also be reacted with
hydrazides (Fig. 5b), and in some cases the resulting hydra-
zone bioconjugates have been reduced to generate more
stable chelator-antibody derivatives [103–106]. A prostate-
targeting hydrazide-linked chelator-antibody (CYT-351) la-
belled with 99mTc (Fig. 5c) has enabled planar and SPECT
imaging of prostate cancer in patients [103].
Glycan-derived aldehydes and ketones have been reacted
with O-alkyl hydroxylamines to form oxime ethers (Fig. 5d).
This covalent attachment is more stable than imine or hydra-
zone linkers and does not require subsequent reduction steps
[107]. This method has been used to prepare a 111In-DOTA-
trastuzumab species, which demonstrates conserved immu-Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002
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Fig. 5. Oxidation of antibody glycan sites generates reactive aldehydes that se
enabling site-speciﬁc attachment of chelators. Such methods have been used t
tetraazacyclododecane-1,4,7,10-tetraacetate) radiolabel. Metal complex charge
8 www.drugdiscoverytoday.comnoreactivity for target HER2 receptors both in vitro and in
tumour bearing mice [108].
Enzymatic modiﬁcation of glycans
Although full-length antibodies have been successfully modi-
fied via glycan oxidation/conjugation, in some cases, the harsh
oxidation conditions can lead to inadvertent oxidation of
methionine residues of the antibody, reducing the serum
half-life of the antibody [109]. A dual enzyme approach that
enables functionalisation of glycans can avoid this: the enzyme
b-1,4-galactosidase removes the terminal galactose residues of
antibodies, and following this, the mutant enzyme b-1,4-galac-
tosyltransferase (Y289L) incorporates a modified galactose unit
containing a reactive functional group at this site [30,110]. This
technology has been applied to site-directed radiolabelling of a
J591 prostate-cancer targeting IgG [30], where the terminal
galactose residue was substituted for a galactose motif contain-
ing an azide. In a copper-free azide/dibenzocyclooctyne cyclo-
addition ‘‘click’’ reaction, the DFO chelator was then
conjugated to the antibody and radiolabelled to give 89Zr-
DFO-J591 IgG (Fig. 6a). This derivative showed higher tumour
uptake than the randomly modified analogue (via lysine mod-
ification with isothiocyanate). Using this strategy, dual fluo-
rescent, 89Zr-radiolabelled antibodies were prepared and
showed efficacy in imaging A33 transmembrane glycoprotein
expression in a colorectal tumour mouse model.ion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
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Fig. 6. Site-directed enzyme-mediated bioconjugation methods utilise (a) b-1,4-galactosyltransferase (Y289L) (b) transglutaminase and (c) sortase A
(SrtA) enzymes. These have been used to incorporate 89Zr-labelled DFO chelator and 64Cu-labelled chelators, CPTA (a 1,4,8,11-tetraazacyclotetradecane
derivative) and MeCOSar (a 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane derivative). Metal complex charges are excluded.Enzyme-mediated conjugation
Recently, protein technology has been developed to enable
enzyme-mediated, site-specific conjugation of a cargo to
target antibodies and proteins [111–114]. These methods
make use of an enzyme that recognises two complementary
motifs on the targeting antibody/protein and the cargo-con-
taining compound. Using these two complementary motifs,
the enzyme catalyses covalent attachment of the targeting
antibody/protein to the cargo. The use of b-1,4-galactosyl-
transferase (Y289L) with DFO chelator (Section ‘‘Reaction
with oxidised hexose groups’’) is an example of this. Other
examples of enzyme-mediated, site-specific conjugation of
chelators to proteins also exist. Like reactions involving
b-1,4-galactosyltransferase (Y289L), such reactions achieve
chemoselective chelator conjugation under mild conditions
that do not denature the antibody.
Transglutaminase
The bacterial transglutaminase (BTG) enzyme catalyses the
formation of a new amide bond between the primary amine
of a lysine side chain and the g-carboxamide group of a gluta-
mine side chain. Many 5-aminopentyl derivatives can act as
lysine side chain surrogates and are recognized by BTG, how-
ever, BTG is only reactive towards glutamine side chains locat-Please cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
https://doi.org/10.1016/j.ddtec.2018.10.002ed in flexible regions of proteins/biomolecules. Glutamine side
chains of IgG antibodies are thus normally unreactive to BTG.
Removal of glycans from position N297 of an IgG antibody,
using the enzyme N-glycosidase F (PNGaseF), results in in-
creased flexibility of this antibody region. This gives rise to
the increased BTG-catalysed reactivity of a glutamine residue,
Q295, in close proximity to N297, and chelators bearing 5-
aminopentyl groups can be site-selectively introduced into this
position in the presence of BTG [115,116]. Reaction of either
anti-L1-CAM chCE7 antibody or rituximab antibody (Fig. 6b),
firstly with PNGaseF to remove N297 glycans, and secondly,
with bifunctional chelators attached to 5-aminopentyl groups
in the presence of BTG, results in IgG mAbs bearing only two
chelators per antibody, attached at position Q295 [115]. Ra-
dionuclide imaging and biodistribution studies in tumour-
bearing mice showed that this site-specific conjugation strate-
gy led to radiolabelled antibodies that provided higher tumour
to non-target organ contrast, compared to antibodies radiola-
belled using conventional, non-specific methods (lysine mod-
ification).
Sortase A
Bacterial enzyme sortase A (SrtA) catalyses a transpeptidase
reaction between an N-terminal glycine, and a specific aminoion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
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acid) [117–119]. SrtA (i) recognizes and cleaves this peptide
sequence between threonine and glycine, and (ii) catalyses
the formation of a new amide bond between threonine and
an N-terminal glycine-containing species. Using this protein
chemistry, a macrobicyclic sarcophagine (a 3,6,10,13,16,19-
hexaazabicyclo[6.6.6]icosane derivative) that binds 64Cu has
been site-selectively appended to a scFv that targets GPIIb/IIIa
glycoprotein receptors overexpressed in thrombosis, athero-
sclerosis and inflammation. Two different conjugation strat-
egies have been described. In the first SrtA-catalysed
conjugation, the scFv, engineered to contain a -Lys-Pro-X-
Thr-Gly- sequence at the C-terminus, was reacted with an N-
terminal glycine residue attached to a sarcophagine chelator
(Fig. 6c) [119]. In the second, the same scFv (in the presence of
Srt A) was reacted with an N-terminal glycine attached to a
strained cyclooctyne [118]. Once purified, the new scFv-
cyclooctyne bioconjugate was reacted chemoselectively with
an azide appended to a sarcophagine ligand. Whilst the first
approach required fewer derivatisations to incorporate a
chelator, the second approach yielded a scFv-octyne biocon-
jugate that is more versatile — it can site-selectively incorpo-
rate any label bearing an azide motif. Both 64Cu-sarcophagine
labelled scFv conjugates enabled PET imaging of GPIIb/IIIa
glycoprotein receptors expressed in thrombosis.
Amino acid coordinating sequences
Peptides and proteins can bind to metal ions via amino acid
side chains, carboxylate groups of C-termini, amine groups of
N-termini, and N atoms of amide groups of the peptide
backbone. Particular sequences of amino acids, containing
several metal-binding ligands, enable direct radiometal com-
plexation by the protein, without the requirement of a syn-
thetic chelator. In such cases, the radiometal-binding amino
acid sequence is simply engineered into the protein at the
desired location.
His tags
The hexahistidine sequence, or His6 tag, originally developed
to aid in protein purification, has been prevalently applied to
incorporate the SPECT isotope, 99mTc (in the form of 99mTc
(CO)3
+), into antibody derivatives [120–126]. The His6 tag is
commonly incorporated at the C-terminus of targeting pro-
teins, although N-terminal incorporation is also possible.
Many 99mTc-labelled proteins have been radiolabelled using
this strategy, with recent examples including a HER2-targeted
sdAb [123], a avb6 integrin-targeted diabody [121] and a
PSMA-targeted diabody [122]. SPECT imaging with these
radiotracers enables visualisation of target tumour tissue.
Computational modelling suggests 99mTc(CO)3
+ coordinates
via two imidazole groups of a His6 tag [127]. Modifications to
the His6 tag have improved protein radiolabelling and bio-
distribution. For example, the inclusion of a thiol-containingPlease cite this article in press as: Morais M, Ma MT. Site-speciﬁc chelator-antibody conjugat
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10 www.drugdiscoverytoday.comcysteine residue to a His6-containing sequence can increase
metallolabelling efficiency [128]. Alternatively, substitution
of His residues in the His6 amino acid sequence can increase
hydrophilicity and negative charge of a radiolabelled protein,
which in turn, can decrease radioactivity retention in non-
target tissue in vivo, leading to improved image contrast. For
example, substituting the sequence HHHHHH for HEHEHE
does not adversely affect 99mTc-radiolabelling of a HER2-
targeted protein, but it does decrease radioactivity retention
in non-target tissue in vivo [129].
Sequences incorporating amide-binding motifs
Several low molecular weight 99mTc radiotracers, including
99mTc-labelled compounds used in renal imaging and 99mTc-
labelled peptides that target cell surface receptors
[19,96,130,131], make use of deprotonated amide groups of
a peptide backbone in combination with deprotonated thiols
to coordinate 99mTcV. Peptide sequences incorporating these
features can be engineered into proteins for efficient binding
of the 99mTcVO3+ motif. The first example of this demonstrat-
ed that Gly4Cys, engineered into the C terminus of a scFv
protein, could be applied to SPECT imaging of a scFv disease
target [132–136]. Subsequent studies have demonstrated that
a scFv protein incorporating a C-terminal 99mTcV(O)-Gly3Cys
sequence has more favourable biodistribution properties (fas-
ter clearance and lower off-target organ retention) than a C-
terminal 99mTcI(CO)3-His6 homologue [136]. Glycine resi-
dues can be substituted for other amino acid residues without
compromising 99mTcV(O) binding abilities [96,134,135,137],
however incorporation of the amino acid binding sequence
Cys-Glyx directly at the N-terminus (instead of Glyx-Cys
directly at the C-terminus) can lead to release of 99mTc
radionuclide in vivo, compromising imaging ability
[133,134].
Summary and concluding remarks
Advances in conjugation chemistry and protein engineering
have enabled development of homogenous radiolabelled
antibodies. New site-specific antibody modification strategies
that have not yet been applied to PET/SPECT imaging with
radiolabelled antibodies could similarly be adapted to gener-
ate well-defined chelator-antibody constructs. Several pre-
clinical studies have highlighted that site-specifically
modified antibodies have improved in vivo behaviour (higher
affinity for target receptors, lower off target accumulation/
persistence, better conjugate stability) relative to those mod-
ified using conventional, less specific methods. Site-specifi-
cally radiolabelled antibody-based radiopharmaceuticals will
deliver new clinically-useful contrast agents for molecular
PET/SPECT imaging, by (i) providing clinicians with better
molecular imaging tools to predict whether a patient will
respond to a particular treatment or intervention, and (ii)
providing scientists with reliable tools to quantitatively mapion for PET and SPECT imaging with radiometals, Drug Discov Today: Technol (2018),
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newly-discovered receptors that are drug targets. Such tech-
nology will also be critically important in providing antibody
conjugates with precisely defined structures and stoichiome-
tries that are acceptable to regulatory authorities.
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